【摘 要】
：
[目的]研究鼻咽癌调强放疗后放射性颞叶损伤的影像及临床特点.[方法]回顾性研究单治疗组2005年3月至2012年1月初治无远处转移鼻咽低分化鳞癌患者行IMRT共260例.依据08分期：Ⅰ期12例(4.6％),Ⅱ期36例(13.8％),Ⅲ期103例(39.6％),Ⅳ期109例(41.9％),局部晚期T3/T4患者共162例,放疗剂量：GTVnx 61.32～76Gy/28～35f,GTVnd 60～
【机 构】
：
江苏省肿瘤医院放疗科 210009
论文部分内容阅读
[目的]研究鼻咽癌调强放疗后放射性颞叶损伤的影像及临床特点.[方法]回顾性研究单治疗组2005年3月至2012年1月初治无远处转移鼻咽低分化鳞癌患者行IMRT共260例.依据08分期：Ⅰ期12例(4.6％),Ⅱ期36例(13.8％),Ⅲ期103例(39.6％),Ⅳ期109例(41.9％),局部晚期T3/T4患者共162例,放疗剂量：GTVnx 61.32～76Gy/28～35f,GTVnd 60～75Gy/28～34f,CTV1 56～60Gy/28～32f,CTV2 50～52Gy/28f.19例患者未行化疗,余患者均进行了以铂类为基础的诱导或同步化疗1～2个周期,仅16例患者行巩固化疗1～3个周期.放疗后行系列MRI随访,末次随访时间2015-1-31.
其他文献
[目的]明确纳米炭—顺铂混悬液对鼻咽癌转移淋巴结有明显治疗效果，证明纳米炭—顺铂混悬液具有靶向化疗作用。[方法]将纳米炭吸附化疗药物顺铂后，注射于鼻咽癌患者鼻咽部病灶，通过纳米炭的靶向输送能力，使化疗药物输送并聚集于鼻咽癌转移的前哨淋巴结，达到定向化疗的目的。严格按照技术要求制备药物后，分两种检验方法进行试验。第一阶段进行纳米炭靶向运药能力研究，设立纳米炭—顺铂混悬液(DDP-CNP)组、顺铂(D
Despite the efficacy of gemcitabine-cisplatin (GC) regimens,the outcome of patients with metastatic nasopharyngeal carcinoma (MNPC) is poor.We conducted a phase Ⅱ trial to determine the safety and eff
Objective:To evaluate the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin chemotherapy regimen followed by concurrent chemoradiotherapy or radiotherapy alone in locoregionally advanced
The aim of this study was to ensure a high dose of intensity modulated radiation therapy(IMRT) was delivered to tumor tissue with a low dose to normal organs.Seldinger interventional techniques were u
Backgroud: For the locogegionally advanced nasopharyngeal carcinoma (NPC) patients, radiotherapy plus chemotherapy has been the gold standard treatment reiment.However, the cisplatin based chemotherap
Background:A randomized phase 3 trial of the treatment of nasopharyngeal carcinoma compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil
Backgroud:Concurrent chemoradiotherapy(CCRT) has been the back-born of locoreginally advanced nasopharyngeal carcinoma (NPC) patients.We report data from our study to assess the efficacy and adverse e
Objective:To investigate the therapeutic efficacy of computed tomography (CT)-guided permanent percutaneous implantation of iodine-125(125I) for treating recurrent nasopharyngeal cancer.
[背景]颅底骨质破坏被认为是鼻咽癌患者一个预后差的指标，并被归于第七版MCC的T3分类，该分期系统是基于二维常规放射治疗作为主要放疗手段及CT作为主要诊断工具的回顾性研究。然而随着放疗技术的发展特别是调强放疗的普遍应用以及影像技术的发展特别是MRI的应用，颅底骨质破坏在鼻咽癌中的预后价值需要重新评估。[目的]探讨基于MRI的颅底骨质破坏在鼻咽癌调强放疗模式下的预后价值；建立一个基于MRI的颅底骨质
Background: Replanning in intensity-modulated radiotherapy(IMRT) has been reported to improve quality of life and local regional control in patients with nasopharyngeal cancer(NPC).Determination of th